Vertex Pharmaceuticals Reports $2.964 Billion Revenue and $1.033 Billion Net Income in Q2 2025

Vertex Pharmaceuticals Incorporated reported significant financial performance for the second quarter of 2025, with total revenues reaching $2.964 billion, a 12% increase from $2.646 billion in the same period of 2024. The growth was primarily driven by strong demand for its flagship cystic fibrosis treatment, TRIKAFTA/KAFTRIO, which generated $2.551 billion in revenue, up 4% year-over-year. Additionally, the company saw early contributions from its recently launched products, including ALYFTREK and JOURNAVX, which collectively added $156.8 million and $12.0 million to the revenue stream, respectively.

In contrast to the previous fiscal period, Vertex experienced a substantial reduction in total costs and expenses, which fell to $1.814 billion from $6.160 billion in the second quarter of 2024. This decrease was largely attributed to the absence of the $4.4 billion in acquired in-process research and development (AIPR&D) expenses related to the acquisition of Alpine Immune Sciences in May 2024. The company reported a net income of $1.033 billion, a significant turnaround from a net loss of $3.594 billion in the prior year, resulting in a diluted earnings per share of $3.99 compared to a loss of $13.92 per share in the same quarter of 2024.

Operationally, Vertex has made strides in expanding its product offerings and market presence. The company has secured reimbursement agreements for ALYFTREK in several countries, including the U.K. and Canada, and is actively working to expand access in additional European markets. The launch of JOURNAVX has also been promising, with over 110,000 prescriptions written since its availability in March 2025. Furthermore, Vertex has activated more than 75 treatment centers for its gene therapy product, CASGEVY, which has been approved in multiple regions, including the U.S. and Europe.

As of June 30, 2025, Vertex reported total cash, cash equivalents, and marketable securities of $12.029 billion, an increase from $11.224 billion at the end of 2024. The company’s working capital also rose to $6.290 billion, reflecting a 4% increase driven by higher cash reserves and inventory levels following recent product launches. Looking ahead, Vertex anticipates continued growth in its cystic fibrosis business and plans to leverage its robust pipeline of therapies targeting various serious diseases, including sickle cell disease and type 1 diabetes. The company remains focused on expanding its market presence and ensuring broad access to its innovative treatments.